4.8 Article

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

期刊

BMC MEDICINE
卷 19, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12916-021-02120-3

关键词

Atrial fibrillation; Clinical phenotypes; Cluster analysis; Clinical management; Major adverse outcomes

资金

  1. Abbott Vascular Int
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol-Myers Squibb
  8. Pfizer Alliance
  9. Alliance Daiichi Sankyo Europe GmbH
  10. Eli Lilly and Company
  11. Edwards
  12. Gedeon Richter Plc.
  13. Menarini Int. Op
  14. MSD-Merck Co.
  15. Novartis Pharma AG
  16. ResMed
  17. Sanofi
  18. SERVIER
  19. Vifor

向作者/读者索取更多资源

In European AF patients, three main clusters were identified, differentiated by the presence of comorbidities. Both non-cardiac and cardiac comorbidities clusters were associated with an increased risk of major adverse outcomes.
Background Epidemiological studies in atrial fibrillation (AF) illustrate that clinical complexity increase the risk of major adverse outcomes. We aimed to describe European AF patients' clinical phenotypes and analyse the differential clinical course. Methods We performed a hierarchical cluster analysis based on Ward's Method and Squared Euclidean Distance using 22 clinical binary variables, identifying the optimal number of clusters. We investigated differences in clinical management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide observational registry. Results A total of 9363 were available for this analysis. We identified three clusters: Cluster 1 (n = 3634; 38.8%) characterized by older patients and prevalent non-cardiac comorbidities; Cluster 2 (n = 2774; 29.6%) characterized by younger patients with low prevalence of comorbidities; Cluster 3 (n = 2955;31.6%) characterized by patients' prevalent cardiovascular risk factors/comorbidities. Over a mean follow-up of 22.5 months, Cluster 3 had the highest rate of cardiovascular events, all-cause death, and the composite outcome (combining the previous two) compared to Cluster 1 and Cluster 2 (all P < .001). An adjusted Cox regression showed that compared to Cluster 2, Cluster 3 (hazard ratio (HR) 2.87, 95% confidence interval (CI) 2.27-3.62; HR 3.42, 95%CI 2.72-4.31; HR 2.79, 95%CI 2.32-3.35), and Cluster 1 (HR 1.88, 95%CI 1.48-2.38; HR 2.50, 95%CI 1.98-3.15; HR 2.09, 95%CI 1.74-2.51) reported a higher risk for the three outcomes respectively. Conclusions In European AF patients, three main clusters were identified, differentiated by differential presence of comorbidities. Both non-cardiac and cardiac comorbidities clusters were found to be associated with an increased risk of major adverse outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据